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Background    There has been no practical guidelines for the management of patients with central 
nervous system (CNS) tumors in Korea for many years. Thus, the Korean Society for Neuro-Oncology 
(KSNO), a multidisciplinary academic society, started to prepare guidelines for CNS tumors from Feb-
ruary 2018.
Methods    The Working Group was composed of 35 multidisciplinary medical experts in Korea. 
References were identified through searches of PubMed, MEDLINE, EMBASE, and Cochrane CEN-
TRAL using specific and sensitive keywords as well as combinations of keywords.
Results    First, the maximal safe resection if feasible is recommended. After the diagnosis of a 
glioblastoma with neurosurgical intervention, patients aged ≤70 years with good performance should be 
treated by concurrent chemoradiotherapy with temozolomide followed by adjuvant temozolomide che-
motherapy (Stupp’s protocol) or standard brain radiotherapy alone. However, those with poor perfor-
mance should be treated by hypofractionated brain radiotherapy (preferred)±concurrent or adjuvant 
temozolomide, temozolomide alone (Level III), or supportive treatment. Alternatively, patients aged >70 
years with good performance should be treated by hypofractionated brain radiotherapy+concurrent 
and adjuvant temozolomide or Stupp’s protocol or hypofractionated brain radiotherapy alone, while 
those with poor performance should be treated by hypofractionated brain radiotherapy alone or temo-
zolomide chemotherapy if the patient has methylated MGMT gene promoter (Level III), or supportive 
treatment.
Conclusion    The KSNO’s guideline recommends that glioblastomas should be treated by maximal 
safe resection, if feasible, followed by radiotherapy and/or chemotherapy according to the individual 
comprehensive condition of the patient.
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INTRODUCTION
Glioblastoma is the most common malignant tumor of the 
central nervous system (CNS), accounting for approximately 
12–15% of all primary intracranial neoplasms and 60–75% 
of glial tumors [1,2]. In most European and North American 
countries and Australia, the annual incidence is about 3–4 
cases per 100,000 population [1]. Its incidence is relatively low 
in Korea, with 0.59 cases per 100,000 population per year [3]. 
In 2004, a randomized phase III trial with glioblastoma pa-
tients showed that concomitant chemoradiotherapy using te-
mozolomide and adjuvant temozolomide in addition to stan-
dard postoperative radiotherapy improved the length of 
survival compared to postoperative radiotherapy alone [4]. 
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Group was composed of 35 medical experts in Korea, includ-
ing 18 neurosurgeons, 8 radiation oncologists, 1 medical on-
cologist, 2 neuroradiologists, 3 pediatric oncologists, 2 pathol-
ogists, and 1 neurologist. As there is no medical specialty for 
neuro-oncology in Korea, neurosurgeons (especially brain tu-
mor surgeon) usually play a role of neuro-oncologists in clini-
cal practice. 
References were identified through searches of PubMed, 
MEDLINE, EMBASE, and Cochrane CENTRAL using spe-
cific and sensitive keywords as well as combinations of key-
words. Abstracts presented at the annual meeting of KSNO in 
September 2018 and the official year-end conference of KSNO 
in December 2018 were also considered relevant. When avail-
able, we also collected existing guidelines from national mul-
tidisciplinary neuro-oncological societies such as the NCCN 
and EANO. The final reference list was generated based on 
originality and relevance to the scope of this guideline. The 
strategy of establishing this guideline was mainly based on 
NCCN and EANO guidelines with modifications and chang-
es according to the unique background of Korea.
Scientific evidence was assessed and graded according to 
the following categories: high level evidence (evaluated from 
multiple populations and derived from randomized clinical 
trials or meta-analysis or systemic review), and low level evi-
dence (evaluated from limited population and derived from 
non-randomized studies, including observational studies, co-
hort studies, and case-control studies).
To establish recommendation levels, the following criteria 
were used. Level I (strong recommendation) required a high 
level evidence and uniform consensus among panels. Level II 
(weak recommendation) required a high level evidence but 
not uniform consensus among panels or low level evidence 
but uniform consensus among panels. Level III (no consen-
sus; individual decision) required a low level evidence but not 
uniform consensus among panels. Level IV (not recommend-
able) required contents being not beneficial or harmful. Rec-
ommendations with level I and level II evidence were not 
marked. However, those with level III and level IV evidence 
were marked at the end of each recommendation in this 
guideline.
DIAGNOSIS OF GLIOBLASTOMAS
When the radiological feature suggests a high-grade glio-
ma, multidisciplinary approach for treatment planning should 
be considered if feasible (Fig. 1). Computed tomography (CT) 
is insufficient to suggest a high-grade glioma even with con-
trast enhancement. Therefore, magnetic resonance image 
(MRI) with contrast enhancement is essential to diagnose a 
high-grade glioma. In order to obtain sufficient tissue for his-
According to a long-term follow-up of a recent randomized 
phase III clinical trial and final results of the trial in 2009 [5], 
this therapeutic approach using temozolomide was consid-
ered the recent standard treatment for glioblastoma patients 
as it increased the median length of survival to 12–15 months 
and showed better outcome for patients with methylated pro-
moter of the O6-methyl guanine DNA methyltransferase 
(MGMT) gene.
To date, many clinical trials have been performed. Many 
trials are also ongoing to overcome this disastrous disease. 
Several new therapeutic modalities such as alternating electric 
field therapy [6] and immunotherapy agents [7] have been 
developed. To apply these new therapeutic strategies for glio-
blastoma patients, well established cancer networks or aca-
demic societies for CNS tumors of western countries such as 
the National Comprehensive Cancer Network (NCCN) [8,9] 
and the European Association for Neuro-Oncology (EANO) 
[10] are updating their guidelines for CNS tumor regularly. 
Therapeutic strategies can be modified according to individ-
ual status of the patient known to be prognostic factors for 
survival in glioblastoma patients including the age of patient, 
performance status, surgical extent, recursive partitioning anal-
ysis class, methylation status of MGMT gene promoter, and 
postoperative chemotherapy and/or radiotherapy [5]. There-
fore, a practical guideline is helpful for patients in detail.
However, the atmosphere for treating glioblastoma patients 
in Korea is different from that in other countries. In Korea, 
the incidence of glioblastoma is relatively lower [3] and the 
overall survival of patients seems to be longer [11] than that 
of western countries. Korean government supports medical 
care financially by the National Health Insurance System which 
has several limitations to apply updated therapeutic modali-
ties to patients.
A practical guideline for the management of patients with 
CNS tumors in Korea is not available. Therefore, the Korean 
Society for Neuro-Oncology (KSNO), a multidisciplinary ac-
ademic society for CNS tumors, bagan to prepare a guideline 
from February 2018. The objective of this guideline is to pro-
vide physicians with evidence-based recommendations and 
consensus expert opinion for the management of patients with 
glioblastomas in daily clinical practice. It will also serve as a 
source of knowledge for institutions and insurance compa-
nies involved in cancer care in Korea.
KSNO GUIDELINE WORKING GROUP
A Working Group was appointed by the KSNO in February 
2018 to establish guidelines on the management of glioblas-
toma patients. The guidelines should be optimized consider-
ing the unique medical circumstance in Korea. The Working 
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topathological diagnosis, neurosurgical intervention is man-
datory even if it is for stereotactic biopsy. To achieve maximal 
safe resection, neuronavigation systems, intraoperative CT or 
MRI, intraoperative ultrasonography, intraoperative mapping 
techniques, and fluorescence-guidance with 5-aminolevuliniv 
acid are recommended. Histopathological diagnosis should 
be officially based on World Health Organization (WHO) 2016 
Classification of Tumors of the Central Nervous System [12]. 
Codeletion of 1p/19q testing and MGMT promoter methyla-
tion test are essential parts of molecular diagnostics for glio-
blastomas. Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) 
mutation test is also required for workup of glioblastomas.
ADJUVANT TREATMENT OF 
GLIOBLASTOMAS
Among glioblastoma patients aged ≤70 years, if the patient 
has good performance status [Karnofsky Performance Scale 
(KPS) ≥60 or Eastern Cooperative Oncology Group (ECOG) 
performance score ≤2], concurrent chemoradiotherapy with 
temozolomide followed by adjuvant temozolomide chemo-
therapy (Stupp’s protocol) [13] or standard brain radiothera-
py alone should be considered. If the patient has poor per-
formance status (KPS <60 or ECOG performance score ≥3), 
hypofractionated brain radiotherapy (preferred)±concurrent 
or adjuvant temozolomide, temozolomide alone (Level III), 
or supportive treatment can be considered. Optional treat-
ment of temozolomide alone for younger glioblastoma pa-
tients with poor performance had low level of evidence with-
out uniform consensus but was recommended. It was decided 
to be included in this guideline (Fig. 2). 
On the contrary, for glioblastoma patients aged >70 years, 
if the patient has good performance status (KPS ≥60 or ECOG 
performance score ≤2), the following therapeutic options 
should be considered: hypofractionated brain radiotherapy+ 
concurrent and adjuvant temozolomide, or concurrent chemo-
radiotherapy with temozolomide followed by adjuvant temo-
zolomide chemotherapy, or hypofractionated brain radio-
therapy alone. If the patient has poor performance status (KPS 
<60 or ECOG performance score ≥3), the following thera-
peutic options should be considered: hypofractionated brain 
radiotherapy alone, temozolomide chemotherapy if methyl-
ated MGMT gene promoter (Level III) is present, or sup-
portive treatment. In poorly performing patients or the elder-
ly, a hypofractionated accelerated course is reasonable with 
the goal of completing the treatment in 2–3 weeks. Optional 
treatment of temozolomide alone for older glioblastoma pa-
tients with poor performance also had low level evidence 
without uniform consensus but was recommended if he/she 
had a methylated MGMT gene promoter. It was decided to be 
included in this guideline (Fig. 3). 
Radiological follow-up using MRI with gadolinium en-
hancement is recommended for regular check-up 2–6 weeks 
after radiotherapy, then every 2–4 months for 3 years, then 
every 6 months regardless of age or therapeutic options (Fig. 
2, 3). There is a uniform consensus among the panel for rou-
tine check of MRI at 2–6 weeks after radiotherapy. In fact, 
MRI at this time can be very informative to detect radiation-
induced brain swelling and pseudoprogression after radio-
therapy. 
KSNO Guidelines version 2018.01
GLIOBLASTOMAS (1): DIAGNOSIS
RADIOLOGICAL
FEATURES
MRI suggestive 
of high grade 
glioma
Multidisciplinary
approach for
treatment 
planning
if feasible
• Maximal safe resction
or
• Partial resection
or
• Biopsy
CLINICAL
IMPRESSION
SURGERY PATHOLOGY
Grade III 
Gliomas
Follow up
protocol
for Grade
III Gliomas
Continue
this
protocol
Glioblastoma
TREATMENT
Fig. 1. Guideline for diagnosis of glioblastoma. To diagnose glioblastoma, MRI with gadolinium enhancement is essential. A multidisciplinary 
approach for treatment planning is recommended if feasible. Glioblastoma should be diagnosed histopathologically for tissues obtained by 
neurosurgical intervention. KSNO, Korean Society for Neuro-Oncology; MRI, magnetic resonance image.
4  Brain Tumor Res Treat  2019;7(1):1-9
KSNO’s Guideline for Glioblastoma
TREATMENT OF RECURRENT 
GLIOBLASTOMA
Diagnosis of glioblastoma recurrence can be indistinguish-
able from pseudoprogression on MRI within the first 3 months 
after completion of concurrent chemoradiotherapy with te-
mozolomide. But, the following radiologic findings can sug-
gest recurrence of glioblastomas; 1) 25% or more increase in 
Fig. 2. Guideline for patients with age ≤70 years. Patients with good performance are recommended to be treated by concurrent chemora-
diotherapy with temozolomide followed by adjuvant temozolomide chemotherapy (Stupp’s protocol) or standard brain radiotherapy alone. 
However, those with poor performance are recommended to be treated by hypofractionated brain radiotherapy (preferred)±concurrent or 
adjuvant temozolomide, temozolomide alone (Level III), or supportive treatment. KSNO, Korean Society for Neuro-Oncology; KPS, Karnof-
sky Performance Scale; ECOG, Eastern Cooperative Oncology Group; MRI, magnetic resonance image.
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GLIOBLASTOMAS (2): ADJUVANT TREATMENT (AGE ≤70)
BASIC CLINICAL FEATURES
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ADJUVANT TREATMENT
Fig. 3. Guideline for patients with age >70 years. Patients with good performance are recommended to be treated by hypofractionated brain 
radiotherapy+concurrent and adjuvant temozolomide, Stupp’s protocol, or hypofractionated brain radiotherapy alone. However, those with 
poor performance are recommended to be treated by hypofractionated brain radiotherapy alone, temozolomide chemotherapy alone if they have 
a methylated MGMT gene promoter (Level III), or supportive treatment. KSNO, Korean Society for Neuro-Oncology; KPS, Karnofsky Perfor-
mance Scale; ECOG, Eastern Cooperative Oncology Group; MRI, magnetic resonance image.
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enhancing lesions despite stable or increasing steroid dose, 2) 
significant increase of the lesion in the fluid-attenuated in-
version recovery (FLAIR) image and T2 weighted image, not 
attributable to other non-tumor causes, and 3) any new le-
sions. Also, if clinical deterioration (not attributable to other 
non-tumor causes and not due to steroid decrease) occurs si-
multaneously, true progression is strongly suggested. If re-
currence is suspected in conventional MRI, it is better to con-
sider the following options; 1) undergoing biopsy, 2) checking 
functional radiologic study such as MR spectroscopy, MR 
perfusion, brain positron emission tomography (PET)-CT, or 
3) checking MRI again and comparing changes that may be 
due to progression versus radiation necrosis. When glioblas-
toma recurrence is suggested clinically and radiologically, 
surgical resection is always recommended, if feasible (Fig. 4). 
Even for surgically unresectable diseases such as diffuse, multi-
focal, and deep located lesions, surgical treatment can be con-
sidered to reduce the mass effect and improve neurological 
symptoms. After surgical resection, the following therapeutic 
options are considered: systemic chemotherapy [bevacizumab 
alone, bevacizumab+irinotecan, daily temozolomide with low 
dose, lomustine or carmustine, PCV (procarbazine+carmustine 
+vincristine) or procarbazine+carmustine], and/or reirradia-
tion (especially if long interval since prior to radiotherapy and/
or if there was a good response to prior radiotherapy), and/or 
supportive treatment if the patient has poor performance sta-
tus (Fig. 4). The efficacy of standard-of-care treatment such 
as adjuvant temozolomide chemotherapy for recurrent glio-
blastoma is suboptimal for salvage purpose. Thus, for eligible 
patients, consideration of clinical trials is highly encouraged.
PRINCIPLES OF THE MANAGEMENT OF 
GLIOBLASTOMAS
Brain imaging
Many imaging modalities are available and used in neuro-
oncology primarily to make treatment decisions in Korea. Im-
aging is always recommended to investigate emergent signs 
or symptoms. 
MRI of the brain (with and without contrast) is the gold 
standard modality to investigate brain tumors. It provides a 
static picture of brain tumors. It has a benefit of providing a 
reasonably good delineation of tumors. In MRI, high grade 
tumors and brain leptomeningeal metastases usually show en-
hancement while low-grade tumors usually do not. However, 
it has a limitation in that it is sensitive to movement. In addi-
tion, metallic objects can cause artifacts. Thus, patients with 
implantable devices cannot receive an MRI. Moreover, claus-
trophobia or renal insufficiency may be an issue. Postopera-
tive brain MRI should be performed within 24–72 hours after 
surgery for gliomas and other tumors to determine the extent 
of resection.
CT scans of the brain (with and without contrast) is usual-
ly considered for patients who cannot undergo an MRI. CT 
Fig. 4. Guideline for recurrent glioblastoma. Surgical resection is always recommended if feasible. Even in surgically unresectable diseases 
such as diffuse, multi-focal, and deep located lesions, surgical treatment can be considered to reduce the mass effect and improve neuro-
logical symptoms. After surgical resection, the following therapeutic options are considered: systemic chemotherapy, and/or reirradiation, 
and/or supportive treatment if poor performance status, and/or enrollment of clinical trials. KSNO, Korean Society for Neuro-Oncology.
KSNO Guidelines version 2018.01
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has a benefit of avoiding claustrophobia or implanted devices 
in the body. It is faster than an MRI. However, CT has a limi-
tation in that it lacks resolution, especially in a tumor located 
within the posterior fossa, and for the patients with renal in-
sufficiency. 
MR spectroscopy can be used to assess metabolites within 
tumor and normal tissues. It may be useful for differentiating 
tumors from radiation necrosis. It may also be helpful in grad-
ing tumors or assessing therapeutic response. The area show-
ing the most abnormal features would be the best place to tar-
get for a biopsy. However, it has limitation for tumors near 
vessels, air space, or bone.
MR perfusion can be used to measure cerebral blood vol-
ume in tumors. It may be useful for differentiating the grade 
of tumor or tumor versus radiation necrosis. The area with 
the highest perfusion would be the best place for a biopsy. 
However, it has limitation for tumors near vessels, air space, 
and bone, or small-volume lesions.
PET-CT using fludeoxyglucose (FDG) has a limitation for 
functional diagnosis of glioblastomas due to high uptake of 
FDG in the brain with normal biologic metabolism. However, 
PET-CT using methionine, which is an essential amino acid, 
may be helpful for differentiating the grade of tumor or tumor 
versus radiation necrosis. But this technology is not commonly 
used in the clinical field in Korea, further development of ap-
plication is necessary for casual use in the clinical practice.
Multidisciplinary care
During treatment, most glioblastoma patients will be man-
aged by various subspecialists. Close and regular communica-
tion among all providers across multidisciplines is essential. 
Utilization of a brain tumor board or multidisciplinary clinic 
care models can facilitate interactions among various subspe-
cialists, ideally including allied health services (e.g., physical, 
occupational and speech therapies, nursing, psychology, and 
social services) to optimize treatment plan recommendations.
As treatment proceeds, it is important that the patient and 
his/her family understand the role of each team member. One 
attending physician who mainly cares for the patient should 
be determined as early as possible and the attending physician 
should contact the patients regularly for follow up. Addition-
ally the attending physician can facilitate referral to the ap-
propriate specialist.
The patient is strongly encouraged to participate in various 
clinical trials. Practitioners should discuss any local, regional, 
and national options for which the patient may be eligible and 
advantages and disadvantages of participation. The center 
that treats neuro-oncology patients should encourage patients 
to participate in large collaborative trials in order to have an-
other option to offer patients.
Throughout treatment, patient’s health-related quality of 
life should remain the highest priority and guide clinical de-
cision-making. While therapeutic response on the radiologic 
study can be a good indicator of successful therapy, other non-
radiologic indicators of therapeutic response such as overall 
well-being, cognitive function, physical and motor function-
ing in day-to-day activities, communication ability, social func-
tioning and family interactions, nutrition, pain control, long-
term consequences of treatment, and psychological issues 
must also be considered.
Patients should be informed of the possibility of pseudo-
progression, its approximate incidence, and potential investi-
gations that may be needed if pseudoprogression is suspected. 
Close follow-up imaging, MR spectroscopy, PET-CT imag-
ing, and repeat neurosurgical intervention including biopsy 
or surgical resection may be necessary, if clinically indicated.
Brain tumor surgery
General principles of surgical resection of glioblastoma are 
as follows: gross total resection when appropriate, minimal 
surgical morbidity, and accurate diagnosis. The following fac-
tors should be considered when deciding the surgical resec-
tion: age, performance status, feasibility of decreasing the mass 
effect with surgery, resectability, including number of lesions, 
location of lesions, time since last surgery in recurrent patients, 
and new versus recurrent tumor [9]. 
Options of surgical resection include gross total resection 
where feasible, stereotactic biopsy, and open biopsy/debulk-
ing followed by planned observation or adjuvant therapy. In 
order to obtain the maximal safe resection, neuronavigation 
systems, intraoperative MRI or CT, intraoperative ultrasonog-
raphy, fluorescence-guided with 5-aminolevulinic acid, and 
intraoperative mapping techniques may be helpful.
For histopathological diagnosis and genetic information, 
sufficient tissue should be sent to the pathologist for neuropa-
thology evaluation and molecular correlates. Frozen section 
analysis, when possible, can help with intraoperative decision 
making. The tissue should be reviewed by an experienced 
neuropathologist. 
Postoperative brain MRI should be performed within 24–
72 hours after surgery for glioblastomas to determine the ex-
tent of resection. The extent of resection should be judged 
based on postoperative imaging study and used as a baseline 
to assess further therapeutic efficacy or tumor progression.
Pathology examination
Incorporation of relevant diagnostic markers, including his-
topathologic and molecular information, which was described 
at the WHO 2016 Classification of Tumors of the Central Ner-
vous System, should be considered as standard practice for 
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tumor classification. Molecular/genetic characterization com-
plements standard histologic analysis, providing additional 
diagnostic and prognostic information that can greatly im-
prove diagnostic accuracy, influence treatment selection, and 
possibly improve management decision-making.
For standard histopathologic examination of glioblastomas, 
basic histologic examination is performed based on the de-
scription in the WHO Classification of Tumors of the Central 
Nervous System [12]. Inter-observer discrepancies in histo-
logic diagnosis and grading are recognized issues due to the in-
herently subjective nature of certain aspects of histopathologic 
interpretation (e.g., astrocytic vs. oligodendroglial morpholo-
gy). In addition, surgical sampling does not always capture all 
relevant diagnostic features in morphologically heterogeneous 
tumors.
Through genetic and molecular testing, glioblastomas can 
be differentiated more accurately in terms of prognosis and, in 
some instances, for response to different therapies. However, 
molecular/genetic characterization does not replace standard 
histologic assessment. It serves as a complementary approach 
to provide additional diagnostic and prognostic information 
that often enhances treatment selection. Although there are 
no identified targeted agents with demonstrate efficacy in 
glioblastoma, the panel encourages molecular testing of tu-
mors such as next generation sequencing because if a driver 
mutation is detected, it may be reasonable to treat patient 
with a targeted therapy on a compassionate use basis, and/
or the patient may have more treatment options in the con-
text of a clinical trial. Molecular testing also has a valuable 
role in improving diagnostic accuracy and prognostic strati-
fication that may inform treatment selection. For example, 
MGMT promoter methylation is an essential part of molecu-
lar diagnostics for all high-grade gliomas and 1p/19q codele-
tion testing is an essential part of molecular diagnostics for 
oligodendrogliomas. Therefore, 1p/19q codeletion testing is 
considered to differentiate astrocytoma from oligodendrogli-
omas. Also, IDH1 and IDH2 mutation testing is required for 
differential diagnosis between IDH mutant and IDH wildtype 
tumors.
Radiotherapy
Optimal timing of radiotherapy after surgical resection is 
not established in glioblastomas. Delay in radiotherapy has 
not been shown to decrease survival. However, we recom-
mend radiotherapy to be initiated at postoperative 2–6 weeks 
after full recovery from surgical interventions. Whenever ra-
diotherapy is planned for glioblastoma patients, pre- and 
postoperative MRIs should be performed to define all target 
volumes, including gross and clinical tumor volume (GTV 
and CTV). Additional MRI at the time of radiotherapy simu-
lation can be used to account for changes in surgical cavity or 
lesions. CT-based 3-dimensional calculation of dose distri-
bution should be performed at any circumstance.
The GTV should encompass preoperative tumor bed and 
enhancing lesions on T1-weighted image of postoperative 
MRI. The preoperative tumor bed should not be directly de-
lineated on the registered preoperative MRI on the planning 
CT in patients undergoing surgical resection. T2/FLAIR sig-
nals can also be included in the GTV if needed. Historical tri-
als and international groups (e.g., RTOG and EORTC) gener-
ally recommend an expansion of 2–2.5 cm for CTV delineation 
to account for subclinical tumor infiltration. However, smaller 
CTV-margins may be reasonable as supported by retrospec-
tive studies (as low as 0.5 cm). Simple expansion from the 
GTV should be avoided. CTV should always be modified 
based on anatomical barriers for tumor infiltrations. A mar-
gin of 3–5 mm from the CTV is usually recommended to cre-
ate the planning target volume to account for errors from im-
age-registration and daily set-up of patients. However, the margin 
can also be reduced if daily image-guidance is performed.
A total dose of 59.4–61.2 Gy is recommended as standard 
radiotherapy using a daily fraction of 1.8–2.0 Gy. A reduced 
field can be used after delivering 45–50.4 Gy. However, field 
reduction does not always need to be performed sequentially. 
When intensity-modulated radiotherapy (IMRT or IMPT) is 
used to avoid critical organs, simultaneous integrated boost 
techniques can be used. For fragile patients with old age or 
poor performance requiring hypofractionated radiotherapy 
in 1–4 weeks, the following dose-fractionation regimens are 
frequently adopted: 40.05 Gy/15 fractions, 34 Gy/10 fractions, 
50 Gy/20 fractions, and 25 Gy/5 fractions. No single scheme 
has been proven to be superior to another. Different schedules 
can also be used based on physician’s decision. The optimal 
margin for CTV expansion has not been established yet. There-
fore, we recommend physicians to follow the principles of 
standard radiotherapy. Absolute cumulative dose limits and 
optimal interval between radiotherapy sessions are not estab-
lished for glioblastomas. Delivery, dose, fraction, target vol-
ume, and techniques for reirradiation should be decided by a 
brain tumor radiation oncologist and through a multidisci-
plinary discussion whenever feasible.
DISCUSSION
We differentiated adjuvant therapeutic strategies based on 
the age of 70 in this study. However, there is no concrete defi-
nition of old age. Many investigators have reported their data 
based on old age of >70 years old. Although there was uni-
form consensus for old age of >70 among panels, a nation-wide 
retrospective multi-institute study can help establish the mean-
8  Brain Tumor Res Treat  2019;7(1):1-9
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ingful age that has the prognostic turning point in Korea.
As mentioned above, almost all medical practices are under 
regulation by the National Health Insurance System in Korea. 
Limited therapeutic modalities were included in this guide-
line. This is because the national system does not cover vari-
ous therapeutic modalities such as electric field therapy, thus 
limiting clinical practice in the field of neuro-oncology in Ko-
rea. The Korean government permits only two therapeutic op-
tions such as concurrent chemoradiotherapy with temozolo-
mide and standard brain radiotherapy alone regardless of the 
methylation status of MGMT promoter after surgery. There-
fore, this guideline does not divide the adjuvant treatment ac-
cording to MGMT promoter methylation status as in other 
guidelines. Although the Korean National Health Insurance 
System does not permit single adjuvant treatment using temo-
zolomide after surgery of glioblastoma, the panel has a con-
sensus that this therapeutic option can be considered for pa-
tients with poor performance status, even in young age, with 
150–200 mg/m2 for 5/28 schedule.
In terms of molecular and genetic diagnosis, only three tests 
were included in this guideline: methylation status of MGMT 
gene promoter, IDH 1/2 mutation, and 1p/19q codeletion. The 
NCCN [9] and EANO guideline [10] recommend more tests 
for genetic alteration of glioblastomas, including ATRX muta-
tion, TERT mutation, and H3F3A mutation. ATRX mutations 
in gliomas are strongly associated with IDH mutations. They 
are nearly always mutually exclusive with 1p/19q codeletion 
[14]. TERT mutations are almost invariably present in 1p/19q 
codeleted oligodendrogliomas. They are found in most glio-
blastomas. TERT mutation, in combination with IDH muta-
tion and 1p/19q codeletion, is characteristic of oligodendrogli-
omas. Absence of TERT mutation, coupled with IDH mutation, 
designates an astrocytoma [15,16]. Histone mutations most 
commonly occur in pediatric midline gliomas (e.g., diffuse in-
trinsic pontine gliomas), although midline gliomas in adults 
can also contain histone mutations [17]. Their presence can 
be considered solid evidence of an infiltrative glioma. This is 
often helpful in small biopsies of midline lesions that may not 
be fully diagnostic with light microscopy or which do not ful-
ly resemble infiltrative gliomas [17]. However, these more com-
plex and detail molecular tests were not included in this guide-
line due to practical limitations at individual institute in Korea.
At recurrence, there is no standard or effective treatment 
for glioblastomas in Korea or western countries. Much less 
regimens can be used for patients, including several alkylat-
ing agents in Korea, than those in other countries. Due to a 
smaller number of glioblastoma patients in Korea, global 
pharmaceutical companies are reluctant to enroll Korean pa-
tients into their clinical trials for new drugs such as immuno-
therapeutic agents. Therefore, chances to participate in clini-
cal trials in Korea are very small. This background results in 
clinical trials to be recommended only at the time of recur-
rence in this guideline. 
This guideline has a marked weakness of limited applica-
tion to Korean patients with glioblastomas due to the unique 
medical atmosphere of Korea. Therefore, it is less helpful for 
physicians treating glioblastoma patients outside of Korea. In 
order to use this guideline globally, neighbor countries close 
to Korea such as Japan or China should have a comprehensive 
network for brain tumor management and cooperate and 
share their guidelines. Further, it will be helpful for Far East-
ern countries to establish a global guideline that is commonly 
applicable to these countries. The next hurdle to be overcome 
is molecular and genetic test for glioblastomas and whole brain 
tumors. Genetic information is now rapidly changing, mak-
ing it difficult to establish definite guideline for clinical prac-
tice. The Consortium to Inform Molecular and Practical Ap-
proaches to CNS Tumor Taxonomy (cIMPACT-NOW) is the 
notable example that shows rapid change in the molecular di-
agnosis of brain tumors [18,19]. Therefore, the KSNO’s Guide-
line Working Group has plans to continue the process of up-
dating guidelines so that the weakness of this version can be 
improved.
CONCLUSIONS
As there was no practical guideline for the management of 
brain tumor patients, the KSNO developed this guideline 
which should be applicable for physicians under unique med-
ical circumstances in Korea. “The KSNO guideline for Glio-
blastoma: version 2018.01” is the first guideline prepared by 
the KSNO Guideline Working Group composed of 35 multi-
disciplinary medical experts in Korea. In summary, glioblas-
tomas should be treated by maximal safe resection if feasible 
followed by radiotherapy and/or chemotherapy according to 
the individual comprehensive condition of patient. As data 
emerging in the past few years have led to significant changes 
in the diagnosis, categorization, and treatment of glioblasto-
ma, we plan to update this guideline consistently. Also, con-
secutive guideline for other brain tumors such as gliomas, brain 
metastasis, and meningiomas will be published by the KSNO 
Guideline Working Group.
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